Pallas Health vs Apex MD
Quarterly billing against a price that already contains the additives.
Pallas Health
Editorial
$216/mo
Pallas Health charges $139 for a first month of compounded semaglutide and $597 every twelve weeks after it, which the seller averages to $199 a month. Twelve weeks is 2.76 calendar months rather than three, so the figure ranked here is $216, and the $897 tirzepatide block works out at $325. Provider care and check-ins are described as included, and the rate is stated as the same at every dose.
Pick it for: Readers who want the lower figure and can commit a quarter at a time
Apex MD
Editorial
$299/mo
Apex MD prices compounded semaglutide at $299 a month by weekly injection and $349 as a daily oral, with tirzepatide at $399 and $419. The injectable preparation is compounded with NAD, B-12 and L-carnitine in the same vial. Plans are described as month-to-month and the rate is stated as flat at every dose.
Pick it for: Readers who want additives priced in rather than added later
Our verdict
Pallas Health bills every twelve weeks at $216. Apex MD charges $299 and states the additives are inside that figure. One spreads the commitment, the other removes a line item.
What actually separates them
Pallas Health and Apex MD state different things about published price. Everything else they publish, they publish the same way.
Apex MD costs $83 more than Pallas Health — 38% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $2,592 at Pallas Health against $3,588 at Apex MD — a difference of $996.
| Pallas Health | Apex MD | |
|---|---|---|
| Published price | $216/mo | $299/mo |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.